US Patent

US12109196 — Non-sedating dexmedetomidine treatment regimens

Method of Use · Assigned to Bioxcel Therapeutics Inc · Expires 2040-07-17 · 14y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of administering high doses of dexmedetomidine to treat agitation in humans with neurodegenerative and/or neuropsychiatric diseases.

USPTO Abstract

Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3935 — chembl-chembl2106195
U-3935 — chembl-chembl2106195

Patent Metadata

Patent number
US12109196
Jurisdiction
US
Classification
Method of Use
Expires
2040-07-17
Drug substance claim
No
Drug product claim
No
Assignee
Bioxcel Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.